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Conclusions: Hypofractionated stereotactic body 
radiotherapy with CyberKnife boost and pelvis radiation 
therapy for prostate cancer has an acceptable toxicity profile 
and favorable biochemical response in both 3-DRT+CK and 
IMRT+CK group, but toxicity was more favorable tendency in 
IMRT+CK treatment group. Additional follow-up is required to 
better evaluate potential toxicity and control rate. 
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Purpose/Objective: The aim of the study was to assess the 
quality of life in prostate cancer patients during the 
stereotactic body radiotherapy treatment. 
Materials and Methods: 91 low and intermediate risk 
localized prostate adenocarcinoma patients were irradiated 
using the CyberKnife Radiosurgical System. The prescription 
dose was 35- 36,25 Gy in five fractions. The assessment of 
the quality of life was measured using the EORTC QLQ-C30 (v 
3.0) questionnaire and a prostate-specific EORTC QLQ-PR25 
module. Patients were asked to fill the form before and at 
the end of the treatment. The further study is designed to 
assess the quality of life during the 2-year follow-up. 
Results: No significant differences were seen in comparison 
of questions measuring Global Health Status before and after 
the treatment (normalized score 60 vs 57). Among all the 
assessed symptoms only the intensification of urinary bothers 
and diarrhoea were found as statistically significant. The 
quality of sexual life has not significantly decreased, however 
among the sexual-specific questions the highest percentage 
of missing data was observed (39%). The tendency of 
improving the level of emotional functioning after the 
radiotherapy was also noticed. 
Conclusions: The study revealed that in spite of 
intensification of urinary and bowel symptoms the global 
quality of life has not significantly changed during the 
treatment what makes the CyberKnife stereotactic body 
radiotherapy a well-tolerated method.  
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Purpose/Objective: Features of high-dose-rate 
brachytherapy (HDR) correspond to biological data that 
suggests hypofractionation as the most suitable way to 
achieve high-dose treatment of prostate cancer. Evaluated 
were our results of combined HDR-boost treatment (HDR-B) 
and 3-dimensional conformal external beam radiotherapy 
(3DCRT). 
Materials and Methods: From October 2006 through April 
2011 88 patients with localized prostate cancer received 
HDR-B of either 3×7 Gy (27/88 patients) or 3×6 Gy (61/88 
patients) delivered through one (80/88 patients) or two (8/88 
patients) procedures and CT (30/88 patients) or MR (58/88 
patients) based planning. Together with 50.4 Gy of 3DCRT 
that in 68/88 patients with increased risk for regional 
metastases (2/3PSA + ((GS – 6) ×10) >13%) included also 
pelvic nodes. Androgen deprivation (AD) was given for a 
mean 24 months to 81/88 patients. Results were compared to 
similar group of 62 successive patients treated solely with 
3DCRT (TD 75.6 Gy/42fx) and AD (in 58/62 patients for mean 
33 months). 18F–Choline PET-CT was used to identify site of 
biochemical relapse. 
Results: HDR-B treatment distinguished by significantly lower 
local failure rate: 8/62 vs. 1/88 patients (p=0.002) – the 
improvement in local control was most distinctive in high-risk 
patients: 7/43 vs. 1/40 patients (p=0.024). Improvement in 5-
year progression-free survival was not significant (97% and 
90% for low/intermediate-risk and 82% and 75% for high-risk 
patients). None of the treatment parameters inclusive dose 
of treatment influenced results of HDR-B. 
Conclusions: Results proved the efficacy of HDR-B. PET-CT 
gives insight of the site of biochemical relapse that is needed 
for the refinement of HDR-B. 
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Purpose/Objective: Over 1,200 Canadian MSM are diagnosed 
with prostate cancer (PCa) each year, and over 8,700 MSM 
have been living with the disease for the past 10 years. With 
early PCa diagnosis, the impact of PCa on sexual function has 
become increasingly important. However, there are few 
studies examining the impact of PCa treatments on sexual 
function for MSM.  
Materials and Methods: MSM were recruited through 
advertising in newspapers, doctors' offices, and word of 
mouth. Participants under the age of 70 treated with curative 
intent for non-metastatic prostate cancer were eligible. 
Individual 45-60 minute semi-structured interviews took 
place face to face or via internet-based video conferencing. 
Sexual function, sexual quality of life, and relationships 
before and after treatment, were discussed. Interviews were 
recorded, transcribed, coded independently by the 
investigators, and analyzed with NVivo. 
Results: Forty three participants were screened with fifteen 
eligible participants (age range = 58-69, mean = 65). The age 
of diagnosis ranged from 55-67 (mean = 58) and the mean 
time from treatment to interview was 6.6 years. Treatment 
modalities included radical prostatectomy (n=8), external 
beam radiation (n = 3), brachytherapy (n = 3), and combined 
radical prostatectomy and external beam radiation (n=1). 
